RxDoctor Payments Data

Jason Ludlow, MD

Ophthalmology · Charleston, WVNPI 1588051791

Payments from drug & device makers

What this record shows

This record is dominated by other: $5,378 of the $7,845 with a category attached, or 68.6%. Alcon accounts for 83.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,782 and has fallen 87.1% since, to $744 in 2025. Among ophthalmology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,845in general payments, 2019–2025

Across 84 payments — averaging $93.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$7K
  • AbbVie$345
  • Johnson & Johnson Surgical Vision, Inc.$330
  • Sight Sciences, Inc.$133
  • Amgen$114
  • Mallinckrodt Hospital Products Inc.$101
  • plus $304 from 11 others

What the payments were for

  • Food & beverage$2,46731%
  • Other$5,37869%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,845 in reported general payments places this provider in the 90th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$292,847
Medicare patients
879
Services billed
2,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$55,419
LumiganBimatoprost41$18,360
XiidraLifitegrast12$17,390
RhopressaNetarsudil Mesylate26$10,682
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat359$7,086
Prednisolone Acetate134$6,972
CombiganBrimonidine Tartrate/Timolol23$6,877
Travoprost31$6,269
Latanoprost659$5,672
CiloxanCiprofloxacin Hcl11$2,735
Brimonidine Tartrate74$2,440
Difluprednate12$2,417
ErythromycinErythromycin Base218$2,200
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha155$1,690
Fluorometholone18$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$345$80,657124 claims
Bausch & Lomb Americas Inc.Xiidra$23$17,39012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →